News

Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

DaVita’s second quarter results surpassed Wall Street’s revenue and adjusted profit expectations, but the market response was notably negative. Management attributed this to a mix of operational and industry-specific challenges, including flat treatment volumes and sequential declines in revenue per treatment, primarily due to a less favorable commercial mix and reduced revenue from phosphate binders. CEO Javier Rodriguez emphasized, “Our growth is mainly performance clinical—that expands life,

(Bloomberg) -- The latest reason to worry about the stock market is quite the doozy: Earnings growth has been too strong. Most Read from BloombergPhoebe Gates Knew Phia Shopping App Took Credit for Sales It Didn’t DriveTrump Weighs Call for Capital Gains Tax Cuts as Midterm BoostTata Sons Chairman to Step Down, Deepening Leadership TurmoilFive Takeaways From Zuckerberg’s 6,500-Word Manifesto on AIEpstein Victim Files Cleared for Release Over Maxwell’s ProtestAs the latest reporting season nears

Mortality gains drove treatment growth despite payor mix headwinds.

DaVita stock has climbed 69.6% over the past three years. After a recent pullback and a strong value score, the current price still raises questions about how much upside investors are actually paying for. Over the past 3 years, DaVita has returned 69.6%, which puts recent share price weakness in the context of a longer period of strong gains. Support for the valuation can come from expectations that DaVita benefits from growing demand for integrated kidney and metabolic care. Execution...

DVA's second-quarter 2026 results show profit growth, but narrowing margins and a weaker commercial mix weigh on the performance.

DaVita's Q2 earnings call highlights mortality-led volume gains and broader middle molecule access, while management held 2026 guidance amid reimbursement pressure.

Moby summary of DaVita Inc.'s Q2 2026 earnings call

DaVita (NYSE:DVA) reported second-quarter results that management said were broadly in line with expectations, supported by accelerating treatment-volume growth and lower mortality among patients. The kidney-care company reaffirmed its full-year 2026 guidance, while outlining plans to expand access

DaVita Inc (DVA) reports adjusted EPS of $4.02 and reaffirms full-year guidance amid successful phosphate binder transition and expanded HD dialyzer rollout.

DaVita HealthCare (DVA) delivered earnings and revenue surprises of +0.25% and +0.61%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

DVA's Q2 results are likely to benefit from volume growth and RPT recovery, but payor mix pressure and spending on technology could limit margin gains.

Dialysis provider DaVita Inc. (NYSE:DVA) will be reporting earnings this Tuesday afternoon. Here’s what you need to know.

Quest Diagnostics' earnings beat, raised 2026 outlook and broad testing demand support momentum, but valuation, debt and margin pressure temper the buy case.

What a time it’s been for DaVita. In the past six months alone, the company’s stock price has increased by a massive 122%, reaching $235.17 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

DaVita is entering earnings with strong momentum as investors look for another quarter of solid execution.

DaVita (DVA) is back in focus after first quarter 2026 revenue and earnings surpassed analysts' expectations, prompting management to lift full year guidance and drawing fresh attention from investors and research desks. See our latest analysis for DaVita. The strong first quarter has come after a powerful run in the stock, with the share price up 27.46% over 90 days and a 67.81% year to date share price return. The 3 year total shareholder return of 97.13% suggests longer term holders have...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at outpatient & specialty care stocks, starting with DaVita (NYSE:DVA).

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

DaVita’s first quarter results were met with a strongly positive market reaction, reflecting operational execution and ongoing cost control. Management attributed the quarter’s outperformance to balanced gains across treatment volume, revenue per treatment, and cost management, aided by productivity improvements and favorable patient outcomes. CEO Javier Rodriguez highlighted the continued momentum of the company’s Integrated Kidney Care (IKC) business, which delivered year-over-year improvement

HIMS reports an adjusted loss and a revenue miss in first-quarter 2026 as gross margin decreases, but it lifts its full-year revenue outlook.